The FDA approved Eli Lilly’s orforglipron (branded Foundayo) on April 1, 2026, as a once-daily oral GLP-1 receptor agonist for weight loss and related conditions. This marks a significant validation for the oral small-molecule GLP-1 category, as it provides a convenient non-injectable option with strong efficacy data (average ~12% weight loss in trials) and flexible dosing without major food/water restrictions. Structure Therapeutics’ aleniglipron, a competing oral GLP-1 agonist, recently reported positive Phase 2 ACCESS II topline results in mid-March 2026, demonstrating placebo-adjusted mean weight loss of up to 16.3% (~39 lbs) at 44 weeks with good tolerability and no apparent plateau. The Lilly approval appears to have lifted sector sentiment for oral GLP-1 developers, driving renewed buying interest in GPCR amid its upcoming End-of-Phase 2 FDA meeting and planned Phase 3 start in 2H 2026. Volume was elevated as traders positioned around the competitive landscape in the obesity market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.